A DEEP INSIGHT ON DIABETIC NEUROPATHY: THE SILENT COMPLICATION OF DIABETES, WITH INPUTS ON ITS CAUSES, DIAGNOSIS, PATHWAYS, AND TREATMENTS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i12.28447Keywords:
Diabetic neuropathy, Diabetes mellitus, Distal symmetric polyneuropathy, Chronic complications, Antidepressant, Ethnomedicine, Pathways of diabetic neuropathyAbstract
Background: The incidence of diabetic neuropathy (DNP) is a prominent complication for people suffering from diabetes. DNP is a common complication in patients suffering from diabetes, and it is affecting approximately more than 50% of the population where the nerves are affected by high glucose levels.
Objective: The aim of the review paper is to inspect the complications, causes, diagnosis, pathogenesis, treatments, pathways, and management of DNP as all these factors play important role in the management of DNP. This paper also aims to identify the potential cures and the side effects if any associated with the commonly used treatments in conditions of DNP.
Methods: The data collected for reviewing was by studying the published researchers from PubMed, Web of Science, Medline, Science Direct, Excerpta Medica Database, Cochrane, Elton B. Stephens Company (EBSCO), and Google open access publications from the year 1995–2017.
Results: We have concluded on an interpretation that the drugs for treating DNP are managing the pain and controlling glucose levels but are reportedly causing major side effects. Hence, attention must be given to the potential risk factors for neuropathy and development of formulations with minimal side effects and a potential cure. We have focused on the recent researches, emerging problems, and techniques for identifying the patients suffering from DNP.
Conclusion: The incidence of DNP is a prominent complication for people suffering from diabetes. Although the treatment available currently focusses on the pain management in DNP, attention must be given to the potential risk factors for neuropathy and development of formulations with minimal side effects and a potential cure.
Downloads
References
Feldman L, Nave KA, Jensen TS, Bennett DL. New horizons in diabetic neuropathy: Mechanisms, bioenergetics and pain. Neuron 2017;93:1296-313.
International Diabetes Federation. Diabetes Atlas. 6th ed. 2014. Available from: http://www.diabetesatlas.org. [Last cited on 2017 Nov 12.
Maji D, Maji T. Neuropathy is the commonest long term complication of Type 2 diabetic individuals at diagnosis. Diabet Metab 2003;2003:2373.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32 Suppl 1:S62-7.
Eaton SB, Eaton SB. Physical inactivity, obesity, and Type 2 diabetes: An evolutionary perspective. Res Q Exerc Sport 2017;88:1-8.
World Health Organization 10 Facts about Diabetes. April, 2016. Available from: http:/www.who.int/features/factfiles/diabetes/en/ index.html. [Last cited on 2017 Oct 12].
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37 Suppl 1:S62-9.
Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison’s Principles of Internal Medicine. 17th ed. New York: Mc Graw-Hill Publisher; 2008. p. 2275.
Zargar AH, Sheikh MI, Bashir M, Masoodi SR, Laway BA, Wani AI, et al. Prevalence of GDM in Kashmiri women in Indian subcontinent. Diabetes Res Clin Pract 2004;66:139-45.
National Health and Medical Research Council. Guidelines for the Management of Type 2 Diabetes Mellitus. 2005. Available from: www. https://nhmrc.gov.au/guidelines-publications/di7-di8-di9-di10-di11- di12-di13. [Last cited on 2017 Sep 06].
Klein R, Klein BE, Moss SE, Davis MD, De Mets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.
Wareham NJ, O’Rahilly S. The changing classification and diagnosis of diabetes. New classification is based on pathogenesis, not insulin dependence. BMJ 1998;317:359-60.
Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. UK prospective diabetes study group. BMJ 1998;317:703-13.
Haslbeck M, Luft D, Neundörfer B, Stracke H, Ziegler D. Diagnosis, Treatment and Follow-up of Diabetic Neuropathy, Diagnosis, Therapy and Follow-up of Sensorimotor Diabetic Neuropathy. 1st ed. German: German Diabetes;
Dyck PJ, Sinnreich M. Diabetic neuropathies. Continuum 2003; Dyck PJ, Sinnreich M. Diabetic neuropathies. Continuum 2003; 9:19–34. 919-34.
Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: Mechanisms to management. Pharmacol Ther 2008;120:1-34.
Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. American diabetes association diabetic neuropathies: A statement by the American diabetes association. Diabetes Care 2005;28:956-62.
Watkins PJ. Pain and diabetic neuropathy. Br Med J 1984;288:168, 169.
Tesfaye S, Price D. In: Boulton AJ, editor. Therapeutic Approaches in Diabetic Neuropathy and Neuropathic Pain, in Diabetic Neuropathy. Carnforth, Lancashire, UK: Marius Press; 1997, pp. 159-81.
Llewelyn JG. The diabetic neuropathies: Types, diagnosis and management. J Neurol Neurosurg Psychiatry 2003;74 Suppl II:ii15-9.
Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: A placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251-2.
Bansal V, Kalita J, Mishra UK. Diabetic neuropathy. Postgrad Med J 2006;82:95-100.
Diabetic Neuropathies: The Nerve Damage of Diabetes. National Institutes of Health, U.S. Department of Health and Human Services, February 2009. Available from: https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies. [Last cited on 2017 Nov 18].
Dyck PJ, Norell JE, Tristler H. Challenges in design of multicenter trials, end point assessed longitudinally for change and monotonicity. Diabetes Care 2007;30:2619-25.
Hébert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. Pain 2017;158;560–8.
Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies, a statement by the American diabetes association. Diabetes Care 2005;28:956-62.
Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. The north-west diabetes foot care study: Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002;19:377-84.
Diabetes Control of Complications Trial Research Group: The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy. The diabetes control and complications trial research group. Ann Intern Med 1995;122:561-8.
Wwlyn JG, Tomlinson DR, Thomas PK, Dyck PJ, Thomas PK. Diabetic Neuropathies in Peripheral Neuropathy. Philadelphia, PA: Elsevier Saunders; 2005. p. 1951-91.
Schumer MP, Joyne SA, Pleiffer MA. Cardiovascular autonomic neuropathy testing in patients with diabetes. Diabetes Spectrum 1998;11:227-31.
Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007;77 Suppl 1:S184-9.
Kawanami D, Matoba K, Utsunomiya K. Signaling pathways in diabetic nephropathy. Histol Histopathol 2016;31:1059-67.
Oates PJ. Aldose reductase still a compelling target for diabetic neuropathy. Curr Drug Targets 2008;9:14-36.
Cameron NE, Cotter MA. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies. Diabet Med 1993;10:593-605.
Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97:12222-6.
Lukic IK, Humpert PM, Nawroth PP, Beirhaus A. The RAGE pathway; Activation and perpetuation in the pathogenesis of neuropathy. Ann N Y Acad Sci 2008;1126:76-80.
Misur I, Zarković K, Barada A, Batelja L, Milicević Z. Turk advanced glycation of end products in peripheral nerve in Type 2 diabetes with neuropathy. Acta Diabetol 2004;41:158-66.
Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999;60 Suppl 4:4-11.
Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: A Cochrane review. J Neurol Neurosurg Psychiatry 2010;81:1372-3.
Haanpää ML, Gourlay GK, Kent JL, Miaskowski C, Raja SN, Schmader KE, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc 2010;85:S15-25.
Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. CMAJ 1998;159:1245-52.
Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr., Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009;4:CD007115.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;3:CD005454.
Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44.
Sindrup SH, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
Raja RK. Painful diabetic neuropathy, continuing education in anaesthesia. Critical Care Pain 2014;14:197-201.
Vinik A. Clinical review: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005;90:4936-45.
LaRoche SM, Helmers SL. The new antiepileptic drugs: Scientific review. JAMA 2004;291:605-14.
Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65-70.
Martini C, Yassen A, Olofsen E, Passier P, Stoker M, Dahan A. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (QutenzaTM) in diabetic neuropathic pain patients: Detection of distinct response groups. J Pain Res 2012;5:51-9.
Quilici S, Chancellor J, Löthgren M, Simon D, Said G, Le TK, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6.
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled cross over trial. Lancet 2009;374:1252-61.
Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in Type 2 diabetes-a randomized placebo controlled study. Acta Neurol Scand 2002;106:248-52.
Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study. Acta Neurol Scand 2006;113:395-404.
Dogra S, Beydoun S, Mazzola J. Oxcarbazepine in painful diabetic neuropathy: A randomized, placebo-controlled study. Eur J Pain 2005;9:543-54.
Eisenberg E, Lurie Y, Braker C, Daoud D. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology 2001;57:505-9.
Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
Wright JM, Oki JC, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997;31:29-34.
Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8.
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116: 109-18.
Lton AJ, Grics FA, Tevel JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diab Med 1998;15:508-14.
Lton AJM, Malik RA, Arezzo JC. Diabetic somatic neuropathy, technical review. Diabetes Care 2004;27:1458-87.
Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 2000;1:131-43.
Erbaş O, Oltulu F, Yılmaz M, Yavaşo A, Taşkıran D. Neuroprotective effects of chronic administration of levetiracetam in a rat model of diabetic neuropathy. Diabetes Res Clin Pract 2016;114:106-16.
Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG. Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci U S A 1982;79:927-30.
Mathews CE, Leiter EH. Constitutive differences in antioxidant defense status distinguish alloxan-resistant and alloxan-susceptible mice. Free Radic Biol Med 1999;27:449-55.
Walde SS, Dohle C, Schott-Ohly P, Gleichmann H. Gleichmann H. Molecular target structures in alloxan-induced diabetes in mice. Life Sci 2002;71:1681-94.
Kim HR, Rho HW, Park BH, Park JW, Kim JS, Kim UH, et al. Role of ca2+ in alloxan-induced pancreatic beta-cell damage. Biochim Biophys Acta 1994;1227:87-91.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001;50:537-46.
Wang J, Wan R, Mo Y, Zhang Q, Sherwood LC, Chien S, et al. Creating a long-term diabetic rabbit model. Exp Diabetes Res 2010;2010:289614.
Andayani TN, Ibrahim MIM, Asdie AH. The association of diabetes related factor and quality of life in Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2010;2:72-5.
Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med 1999;107 Suppl:34S-42.
Bhadada SK, Sahay RK, Jyotsna VP, Agrawal JK. Diabetic neuropathy: Current concepts. J Indian Acad Clin Med 2001;2:305-16.
Bordoloi R, Dutta KN. A review on herbs used in the treatment of diabetes mellitus. J Pharm Chem Biol Sci 2014;2:86-92.
Rupeshkumar M, Kavith K, Haldar PK. Role of herbal plants in the diabetes mellitus therapy: An overview. Int J Appl Pharm 2014;6:1-3.
Ibrahim R. Diabetes mellitus Type II: Review of oral treatment options. Int J Pharm Pharm Sci 2010;2:36-41.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
